Ontology highlight
ABSTRACT:
SUBMITTER: Zeng Z
PROVIDER: S-EPMC5342403 | biostudies-literature | 2016 Aug
REPOSITORIES: biostudies-literature
Zeng Zhihong Z Wang Rui-Yu RY Qiu Yi Hua YH Mak Duncan H DH Coombes Kevin K Yoo Suk Young SY Zhang Qi Q Jessen Katti K Liu Yi Y Rommel Christian C Fruman David A DA Kantarjian Hagop M HM Kornblau Steven M SM Andreeff Michael M Konopleva Marina M
Oncotarget 20160801 34
mTOR activation leads to enhanced survival signaling in acute myeloid leukemia (AML) cells. The active-site mTOR inhibitors (asTORi) represent a promising new approach to targeting mTOR in AKT/mTOR signaling. MLN0128 is an orally-administered, second-generation asTORi, currently in clinical development. We examined the anti-leukemic effects and the mechanisms of action of MLN0128 in AML cell lines and primary samples, with a particular focus on its effect in AML stem/progenitor cells. MLN0128 in ...[more]